Sui Group Targets 5% of Circulating Supply in Strategy Shift
Sui Group Holdings (SUIG), the sole Nasdaq-listed company officially affiliated with the Sui Foundation, announced on January 25, 2026, a significant strategic pivot from a digital asset treasury (DAT) to an integrated operating company. The firm, which currently holds 108 million SUI tokens valued at approximately $160 million, is now focused on accumulating SUI and building infrastructure to generate recurring yield. Chief Investment Officer Steven Mackintosh stated the near-term goal is to increase the company's stake to 5% of SUI's circulating supply. This shift has already seen its SUI per share metric increase from 1.14 to 1.34.
SuiUSDE Launch in February to Fuel SUI Buybacks
The core of the new strategy is the launch of SuiUSDE, a native, yield-bearing stablecoin built by white-labeling Ethena's technology. Expected to go live in February, the stablecoin is designed to channel 90% of its generated fees back to Sui Group and the Sui Foundation, which will be used to either buy back SUI on the open market or reinvest into the Sui DeFi ecosystem. This creates a direct mechanism to drive value to the SUI token. Further diversifying its income, Sui Group has also entered a revenue-sharing agreement with Bluefin, the leading perpetual futures DEX on Sui, to capture a percentage of its trading fees. "Perps are the killer use case in crypto," Mackintosh noted, emphasizing the move from a passive holder to an active operator.
Firm Targets 6% Yield Citing Capital Discipline
Sui Group aims to boost its effective yield to around 6%, well above SUI's base staking yield of 2.2%, by layering these new operating revenues. Mackintosh believes this, combined with SUI's structurally deflationary tokenomics, creates a compelling long-term growth model for the company's SUI-per-share metric. He contrasted this model with other DATs that faced forced token sales during market downturns. Citing the company's discipline, he pointed to its $22 million cash reserve and a recent buyback of 8.8% of its own shares as proof of a patient strategy that avoids financial engineering and provides stability.
